{"schema_version":"secwatch.filing_event.v1","accession":"0001434647-26-000015","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.075100+00:00","generated_at":"2026-05-15T11:32:42.091507+00:00","sec_items":["1.01","1.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra sells SDX portfolio to Commave for $50M, settles lawsuit, repays $63M debt","bullets":["Total purchase price $50M; $25M at signing, $20M within 10 business days, $5M after records delivery.","Litigation with Commave in Delaware Chancery dismissed with prejudice; both parties release all claims.","Repaid $63M term loan (incl. $3M PIK interest) in full, terminating Credit Agreement and all liens.","CEO Neil McFarlane highlights debt-free balance sheet and enhanced financial flexibility.","Commave receives worldwide royalty-free perpetual license to SDX patents retained by Zevra."],"urls":{"canonical":"https://secwatch.observer/filing/0001434647-26-000015","json":"https://secwatch.observer/filing/0001434647-26-000015.json","markdown":"https://secwatch.observer/filing/0001434647-26-000015.md","text":"https://secwatch.observer/filing/0001434647-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/0001434647-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/zvra-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:32:42.091507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66c23b1119aad6665373932c05c6ffbb1c3fe35a","claim":"ZEVRA THERAPEUTICS, INC. entered into Asset Purchase and Settlement Agreement with Commave Therapeutics SA valued at $50.0 million (effective 2026-03-13).","evidence_excerpt":"On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Collaboration and License Agreement between the parties dated September 3, 2019, as amended (the “AZSTARYS License Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/0001434647-26-000015-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Commave Therapeutics SA"},{"label":"Value","value":"$50.0 million"},{"label":"Effective","value":"2026-03-13"}]},{"claim_id":"6caaadf42b12d6e275f411d6f2eb7dbfc9888892","claim":"ZEVRA THERAPEUTICS, INC. terminated Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC valued at $63.0 million (effective 2026-03-12).","evidence_excerpt":"On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/0001434647-26-000015-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC"},{"label":"Value","value":"$63.0 million"},{"label":"Effective","value":"2026-03-12"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}